My Recent Searches
- No Recent Search.
My Tests Viewed
- No Test Viewed.
Acute Myeloid Leukemia Prognostic Panel (Normal Karyotype)
81403, 81310, 81245, 81479
CEBPA Mutation Analysis; NPM (Exon 12) Mutation Analysis, Cell-based; FLT3 (ITD) and D835 Variant Detection PCR
See individual tests
See inidividual tests
This testing, consisting of FLT3, NPM-1, and CEBPA, is recommended in the NCCN guidelines for determination of AML risk status in patients with cytogenetically normal AML. The presence of CEBPA gene mutations is associated with increased disease-free survival and overall survival. Mutations in NPM1 gene is a predictor of favorable prognosis and good response to induction chemotherapy. The presence of (FLT3) internal tandem duplication is associated with short disease-free survival.
To view specimen requirements and codes please Select a regional laboratory.
Not sure which laboratory serves your office? Call us 866-MYQUEST (866-697-8378)
Reference ranges are provided as general guidance only. To interpret test results use the reference range in the laboratory report.
(The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.)
* The tests listed by specialist are a select group of tests offered. For a complete list of Quest Diagnostics tests, please refer to our Directory of Services.